Summit Therapeutics (SMMT) Competitors $28.67 +1.10 (+3.99%) Closing price 04:00 PM EasternExtended Trading$28.69 +0.02 (+0.07%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT vs. MRK, GSK, TAK, ARGX, ONC, BNTX, INSM, TEVA, GMAB, and RDYShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Merck & Co., Inc. (MRK), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. Summit Therapeutics vs. Its Competitors Merck & Co., Inc. GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Which has higher valuation & earnings, MRK or SMMT? Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerck & Co., Inc.$63.92B3.33$17.12B$6.8712.35Summit Therapeutics$700K30,417.64-$221.32M-$0.34-84.32 Is MRK or SMMT more profitable? Merck & Co., Inc. has a net margin of 27.27% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 43.23% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Merck & Co., Inc.27.27% 43.23% 17.11% Summit Therapeutics N/A -62.87%-51.61% Do institutionals & insiders believe in MRK or SMMT? 76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.1% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, MRK or SMMT? Merck & Co., Inc. has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500. Does the media prefer MRK or SMMT? In the previous week, Merck & Co., Inc. had 66 more articles in the media than Summit Therapeutics. MarketBeat recorded 74 mentions for Merck & Co., Inc. and 8 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.22 beat Summit Therapeutics' score of 1.14 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 55 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer MRK or SMMT? Merck & Co., Inc. currently has a consensus target price of $108.69, indicating a potential upside of 28.14%. Summit Therapeutics has a consensus target price of $34.67, indicating a potential upside of 20.92%. Given Merck & Co., Inc.'s higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merck & Co., Inc. 1 Sell rating(s) 12 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.43Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 SummaryMerck & Co., Inc. beats Summit Therapeutics on 13 of the 17 factors compared between the two stocks. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.29B$2.82B$5.74B$9.51BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-84.329.0428.1120.03Price / Sales30,417.64744.02461.37103.88Price / CashN/A166.2336.5559.01Price / Book54.095.168.655.90Net Income-$221.32M$30.99M$3.25B$258.66M7 Day Performance9.43%7.74%4.20%2.23%1 Month Performance34.79%16.18%10.82%12.76%1 Year Performance173.31%-1.03%34.70%19.36% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.1494 of 5 stars$28.67+4.0%$34.67+20.9%+176.3%$21.29B$700K-84.32110Positive NewsMRKMerck & Co., Inc.4.997 of 5 stars$79.96-1.9%$108.69+35.9%-33.1%$200.63B$64.17B11.6375,000Positive NewsUpcoming EarningsDividend AnnouncementGSKGSK1.7307 of 5 stars$36.28-0.5%$37.38+3.0%-2.8%$74.36B$40.10B18.7268,629Trending NewsUpcoming EarningsAnalyst RevisionTAKTakeda Pharmaceutical1.6897 of 5 stars$14.42-2.2%N/A+8.0%$45.90B$30.09B65.5747,455Upcoming EarningsARGXargenex3.6785 of 5 stars$564.70-1.4%$728.06+28.9%+27.4%$34.58B$2.25B34.851,599Trending NewsUpcoming EarningsAnalyst RevisionONCBeOne Medicines1.2886 of 5 stars$294.30+1.4%$327.56+11.3%N/A$32.26B$3.81B-79.1111,000Insider TradeGap UpBNTXBioNTech1.409 of 5 stars$110.03-0.9%$136.58+24.1%+37.8%$26.49B$2.98B-32.416,772News CoverageINSMInsmed3.9464 of 5 stars$102.55-1.6%$108.47+5.8%+39.1%$19.43B$363.71M-17.211,271Positive NewsAnalyst ForecastInsider TradeTEVATeva Pharmaceutical Industries4.166 of 5 stars$16.07-1.4%$24.71+53.8%-0.8%$18.44B$16.54B-13.9836,830Positive NewsUpcoming EarningsGMABGenmab A/S4.0631 of 5 stars$21.89-0.6%$37.80+72.7%-15.2%$14.04B$3.12B12.442,682Positive NewsRDYDr. Reddy's Laboratories2.7247 of 5 stars$14.49-1.4%$16.95+17.0%-8.1%$12.09B$3.81B21.9527,811Earnings Report Related Companies and Tools Related Companies Merck & Co., Inc. Competitors GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Insmed Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMMT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
